July 30, 2014

Campath-Based Tx Lowers Risk of Kidney Rejection

There are a lot of regimens being tried in transplant, and most include calcineurin inhibitors that have significant toxicity," Anupam Agarwal, MD, of the University of Alabama at Birmingham, told MedPage Today. "Hence, if one could safely reduce the dose of the calcineurin inhibitor and still benefit from its immunosuppressive properties, it would be huge advance."

UAB in the News

 
 
Back to Top